Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 8/20 | 0.53 |
| ▸ | CA1 | P00915 | 8/20 | 0.53 |
| ▸ | CA2 | P00918 | 8/20 | 0.53 |
| ▸ | CA9 | Q16790 | 8/20 | 0.53 |
| ▸ | CA4 | P22748 | 2/20 | 0.53 |
| ▸ | CA6 | P23280 | 2/20 | 0.53 |
| ▸ | CA5A | P35218 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | EDNRA | P25101 | 1/20 | 0.34 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6179639 | 0.98 | CA12 (0.55) | CA12CA1CA2CA9CA4 | |
| SCHEMBL5039363 | 0.96 | CA12 (0.53) | CA12CA1CA2CA9CA4 | |
| SCHEMBL10105631 | 0.81 | CHRNA7 (0.45) | CA12CA1CA2CA9CA4 | |
| SCHEMBL1040641 | 0.79 | CHRNA7 (0.38) | CA12CA1CA2CA9CA4 | |
| SCHEMBL5002545 | 0.79 | FABP3 (0.40) | CA12CA1CA2CA9CA4 | |
| SCHEMBL12186143 | 0.78 | CHRNA7 (0.38) | CHRNA7ALDH1A1KDM4EGAAMAPT | |
| SCHEMBL25825555 | 0.75 | EDNRA (0.42) | CHRNA7ALDH1A1KDM4ELMNAGAA | |
| Potassium SCHEMBL6789782 | 0.75 | CA12 (0.59) | CA12CA1CA2CA9CA4 | |
| SCHEMBL15044962 | 0.74 | CHRNA7 (0.41) | CHRNA7ALDH1A1KDM4ELMNAGAA | |
| SCHEMBL25836464 | 0.73 | ALDH1A1 (0.39) | ALDH1A1KDM4ELMNAGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1149091-B1 | 4-(HETEROCYCLYLSULFONAMIDO)-5-METHOXY-6-(2-METHOXYPHENOXY)-2-PHENYL- OR PYRIDYLPYRIMIDINES AS ENDOTHELIN RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-03-19 | — | — | EP | disclosed |
| EP-1185525-B1 | 4-HETEROCYCLYLSULFONAMIDYL-6-METHOXY-5-(2-METHOXY-PHENOXY)-2-PYRIDYL-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-02-07 | — | — | EP | disclosed |
| EP-0897914-B1 | Process for the preparation of 2,5-disubstitued pyridines | HOFFMANN LA ROCHE (CH) | 2004-05-26 | — | — | EP | disclosed |
| US-6720322-B2 | USE AS ENDOTHELIN RECEPTOR ANTAGONISTS. | ACTELION PHARAMCEUTICALS LTD. (CH) | 2004-04-13 | — | — | US | disclosed |
| US-6596719-B1 | Manufacturing those compounds, pharmaceutical compositions containing one or more of those compounds as endothelin antagonists, and a method of treating a subject having a disorder involving endothelin with the compounds of the | ACTELIO PHARMACEUTICALS LTD. (CH) | 2003-07-22 | — | — | US | disclosed |
| US-20030087920-A1 | Butyne diol derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2003-05-08 | — | — | US | disclosed |
| US-6521631-B2 | N-(6-methoxy-5-(2-methoxy-phenoxy)-2-pyridin-4-yl-pyrimidin-4 -yl)) 5-isopropyl-pyridine-2-sulfonamide; treatment of disorders which are associated with abnormal vascular tone and endothelial dysfunction. | HOFFMANN-LA ROCHE INC. | 2003-02-18 | — | — | US | disclosed |
| EP-1244637-A1 | BUTYNE DIOL DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2002-10-02 | — | — | EP | disclosed |
| US-20020137933-A1 | Heterocyclic sulfonamides | BREU VOLKER (DE) | 2002-09-26 | — | — | US | disclosed |
| US-6417360-B1 | ENDOTHELIN RECEPTOR INHIBITORS; CARDIOVASCULAR DISORDERS, HEART FAILURE | HOFFMANN-LA ROCHE INC. | 2002-07-09 | — | — | US | disclosed |
| US-6242601-B1 | ENDOTHELIN RECEPTORS INHIBITORS SUCH AS 4-(4-METHOXY-5-(2-METHOXY-PHENOXY)-6-(5-METHYL-PYRIDINE-2-SULF ONYLAMINO)-PYRIMIDIN-2-YL)-PYRIDINE-2-CARBOXYLIC ACID USED TO TREAT CARDIOVASCULAR SYSTEM DISORDERS | HOFFMAN-LA ROCHE INC. | 2001-06-05 | — | — | US | disclosed |
| EP-0713875-B1 | Sulfonamides | HOFFMANN LA ROCHE (CH) | 2001-03-21 | — | — | EP | disclosed |
| WO-2001017976-A1 | BIS-SULFONAMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2001-03-15 | — | — | WO | disclosed |
| WO-2000052007-A1 | 4-HETEROCYCLYSULFONAMIDYL-6-METHOXY-5-(2-METHOXY-PHENOXY)-2-PYRIDYL-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-09-08 | — | — | WO | disclosed |
| WO-2000042035-A1 | 4-(HETEROCYCLYLSULFONAMIDO) -5-METHOXY-6- (2-METHOXYPHENOXY) -2-PHENYL- OR PYRIDYLPYRIMIDINES AS ENDOTHELIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-07-20 | — | — | WO | disclosed |
| US-6080866-A | A CHEMICAL INTERMEDIATES FOR ENDOTHELIN RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2000-06-27 | — | — | US | disclosed |
| EP-0897914-A1 | Process for the preparation of 2,5-disubstitued pyridines | F. HOFFMANN-LA ROCHE AG (CH) | 1999-02-24 | — | — | EP | disclosed |
| US-5837708-A | CARDIOVASCULAR DISORDERS OF HYPERTENSION, ISCHEMIA, ANGINA PECTORIS AND VASOSPASMS | HOFFMANN-LA ROCHE INC. (US) | 1998-11-17 | — | — | US | disclosed |
| WO-1996016963-A1 | SULFONAMIDES AND THEIR USE AS MEDICAMENTS | F. HOFFMANN-LA ROCHE AG (CH) | 1996-06-06 | — | — | WO | disclosed |
| EP-0713875-A1 | Sulfonamides | F. Hoffmann-La Roche AG (CH) | 1996-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087920-A1 | Butyne diol derivatives | BDKRB2, EDNRB, EDNRA | CA12 4225/4885CA1 4259/4885CA2 2432/4885 |
| US-20020137933-A1 | Heterocyclic sulfonamides | ECE1, EDNRA, EDNRB | CA12 3262/4885CA1 2330/4885CA2 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.